The Cisplatin Gap Closes: AstraZeneca's VOLGA Trial Rewrites the Standard of Care for Bladder Cancer

AstraZeneca's VOLGA Phase 3 trial delivers a statistically significant overall survival benefit for cisplatin-ineligible muscle-invasive bladder cancer patients, marking a turning point for a population that has long been underserved by perioperative treatment options.

After Makary: What the FDA's Leadership Vacuum Means for Drug Development

Marty Makary's sudden resignation as FDA commissioner leaves the pharmaceutical industry facing regulatory uncertainty at a critical moment for biotech recovery.

The Pill That Changed Everything: FDA Approves First All-Oral AML Regimen for Elderly Patients

The FDA approves Inqovi in combination with venetoclax as the first all-oral treatment for elderly patients with newly diagnosed AML, eliminating the need for frequent infusion center visits.

The Promise That Couldn't Scale: What Sarepta's Elevidys Decline Reveals About Gene Therapy's Commercial Ceiling

Sarepta's Elevidys gene therapy beats revenue estimates but faces declining sales, revealing the gap between clinical promise and commercial durability in the gene therapy sector.

No Antibody, No Problem: How argenx Just Rewrote the Rules for Myasthenia Gravis Treatment

argenx's VYVGART receives FDA approval for all generalized myasthenia gravis patients regardless of serotype, including the triple seronegative population previously excluded from treatment options.

The Slide That Sees Everything: What Roche's $1 Billion PathAI Bet Reveals About the Future of Cancer Diagnosis

Roche's $1.05 billion acquisition of PathAI signals that AI-powered digital pathology is becoming as strategically important as drug development itself in precision oncology.

Bayer's $2.45 Billion Bet on Blindness: What the Perfuse Deal Reveals About the Next Frontier in Eye Disease

Bayer's $2.45 billion acquisition of Perfuse Therapeutics signals a strategic shift in ophthalmology toward disease-modifying treatments that could reverse vision loss in glaucoma and diabetic retinopathy—conditions affecting over 200 million people worldwide.

The Half That Was Left Behind: How Cytokinetics Just Opened the Door for Non-Obstructive HCM

Cytokinetics' ACACIA-HCM Phase 3 trial just delivered the first statistically significant win in non-obstructive HCM. Here is what the data mean, why the disease has been so hard to treat, and what comes next for aficamten and the field.

The $10 Million Drug That Could Be Worth Billions: How Celcuity's Gedatolisib Just Rewrote the Breast Cancer Playbook

In 2021, Pfizer sold a drug candidate for $10 million upfront. This week, that same drug delivered a Phase 3 win that could reshape the treatment of the most common form of breast cancer and generate more than $2 billion in annual sales.

The Immune Reset Bet: Why UCB Just Paid $2.2 Billion for a T-Cell Engager

UCB's $2.2 billion acquisition of Candid Therapeutics signals a fundamental shift in autoimmune treatment strategy. T-cell engagers could reshape immunology the way CAR-T transformed oncology.

The Trial That Never Stops: How the FDA's Real-Time Clinical Trial Push Could Reshape Drug Development

The FDA has launched proof-of-concept real-time clinical trials with AstraZeneca and Amgen, signaling a fundamental shift in how drug development data is monitored and regulatory decisions are made.

The D1 Difference: Why Teva's $700 Million Bet on Ecopipam Could Rewrite Tourette Syndrome Treatment

Teva Pharmaceutical Industries' $700 million acquisition of Emalex Biosciences brings ecopipam, a first-in-class D1 receptor antagonist, to pediatric Tourette syndrome treatment—challenging decades of dopamine D2-targeting therapy.